Loading news...
Shares of Evolent Health, Inc (NYSE: EVH - Get Free Report) have earned an average recommendation of "Moderate Buy" from the sixteen ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and fourteen have issued a buy recommendation on
WASHINGTON, Jan. 2, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, announced that the Compensation Committee of Evolent's Board of Directors approved the grant of a one-time time-based restricted stock unit award covering 587,500 shares of Evolent Class A common stock, par value $0.01 per share (the "Inducement Award"), to Mr. Mario Ramos ("Mr.
Investors need to pay close attention to EVH stock based on the movements in the options market lately.
Evolent Health, Inc. ( EVH ) UBS Global Healthcare Conference 2025 November 11, 2025 5:00 PM EST Company Participants John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Presentation Kevin Caliendo UBS Investment Bank, Research Division Good afternoon. This is Kevin Caliendo, health care service and distribution and IT analyst from UBS.
Evolent Health, Inc. ( EVH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Seth Blackley - Co-Founder, CEO & Director John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division John Stansel - JPMorgan Chase & Co, Research Division Lucas Romanski - TD Cowen, Research Division Eduardo Ron - Truist Securities, Inc., Research Division Jeffrey Garro - Stephens Inc., Research Division Jessica Tassan - Piper Sandler & Co., Research Division David Larsen - BTIG, LLC, Research Division Matthew Shea - Needham & Company, LLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Presentation Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter ended September 30, 2025. As a reminder, this conference call is being recorded.
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Evolent Health (EVH) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.04 per share a year ago.
WASHINGTON , Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, and American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced a new model enabling high-quality, more affordable, and connected cancer care — all without relying on prior authorization. The national partnership seeks to improve clinical decision-making by introducing quality-focused interventions, driving clinical insights through an innovative data and analytics platform, and rewarding providers for high-quality care.
Q3 2025 financial results ahead of expectations. Announces more than $500 million in newly-contracted annualized revenue to launch in 2026.
Company to Participate in Upcoming Conferences WASHINGTON , Oct. 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path. Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to Evolent's free cash flow by more than $7 million per year.
CVS shows revenue growth and raised guidance, while EVH faces revenue declines but pursues oncology deals and efficiency gains.
Evolent's revenue dip in Q1 was structural, not demand-driven, and Q2 shows stabilization; I expect growth to resume in the second half of 2025. New specialty contracts, incremental member growth, and key leadership appointments should drive recovery and enhance clinical and financial credibility. The oversubscribed convertible notes offering signals investor confidence, strengthens liquidity, and supports shareholder value through buybacks and reduced refinancing risk.
WASHINGTON , Aug. 19, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced the pricing of $145.0 million aggregate principal amount of 4.50% convertible senior notes due 2031. The notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
WASHINGTON , Aug. 18, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced that it intends to offer $140.0 million aggregate principal amount of convertible senior notes due 2031, subject to market and other conditions. Evolent also expects to grant the initial purchasers in the proposed offering an option to purchase up to an additional $20.0 million aggregate principal amount of notes.
Evolent Health, Inc. (NYSE:EVH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants John Paul Johnson - Chief Financial Officer Seth Barrie Blackley - Co-Founder, CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division Daniel R. Grosslight - Citigroup Inc., Research Division Eduardo Enrique Ron - Truist Securities, Inc., Research Division Jared Phillip Haase - William Blair & Company L.L.C.
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Evolent Health (EVH) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of $0.09. This compares to earnings of $0.3 per share a year ago.
EVH Earnings Drop 31%
WASHINGTON , Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year.